Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...
September 12, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...
September 11, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...
September 10, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...
August 27, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
July 31, 2025 16:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
July 28, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
July 11, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics to Present at the Advanced Wound Care Summit USA

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
July 09, 2025 08:30 ET | Source: FibroBiologics, Inc.

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
July 07, 2025 16:35 ET | Source: FibroBiologics, Inc.

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...